Skip to content Skip to footer
Subscribe Now
Viewpoints_Salom Juethner
VIEWPOINTS

PharmaShots Interview: Takeda Salom Juethner Shares Insights on the Data Publication to Support the Sustained Safety and Efficacy of Takhzyro

In an interview with PharmaShots, Salomé Juethner, Senior Medical Director, Rare Diseases at Takeda shared her views on the P-III HELP study of Takhzyro for the prevention of hereditary angioedema attacks in the Journal AllergyShots:The P-III HELP OLE study evaluates the safety & efficacy of Takhzyro (300mg, q2w) in 212 patients aged =12yrs. with HAE attacks for ~2.5yrs.…
October 6, 2021

Read more

Viewpoints_Ahmet Sezer, Karl Lewis, and Israel Lowy
VIEWPOINTS

PharmaShots Interview: Dr. Ahmet Sezer, Karl Lewis, and Regeneron’s Israel Lowy Share Insights on Libtayo (cemiplimab) for NSCLC & BCC

In an interview with PharmaShots, Dr. Ahmet Sezer, (Professor in the Department of Medical Oncology at Baskent University), Karl Lewis (Professor in the Division of Medical Oncology at the University of Colorado) and Israel Lowy (Senior Vice President, Translational and Clinical Sciences, Oncology at Regeneron) shared their views on the EC's approval of Libtayo for…
September 29, 2021

Read more

Viewpoints_Dr. David Kendall
VIEWPOINTS

PharmaShots Interview: Zealand Pharma’s Dr. David Kendall Shares Insights on Zegalogue for Severe Hypoglycemia in Pediatric and Adult Patients with Diabetes

In an interview with PharmaShots, Dr. David Kendall, Senior Global Medical Advisor at Zealand Pharma shared his views on the availability of Zegalogue in the US for severe hypoglycemia in pediatric and adult patients with diabetes & its availability in both an auto-injector and a prefilled syringeShots:The company reported the availability of Zegalogue (0.6mg/0.6mL) in the US…
September 27, 2021

Read more

Viewpoints_Dr. David Spetzler
VIEWPOINTS

PharmaShots Interview: Caris Life Sciences’ Dr. Spetzler Shares Insight on AI-Based MI FOLFOXai Predictor

In a recent interview with PharmaShots, Dr. Spetzler, President and Chief Scientific Officer of Caris Life Sciences shared his insights on FOLFOXai and its importance in patients with metastatic colorectal cancer. He also highlights the data supporting the use of FOLFOXai as a predictor of CT efficacy in patients with mCRC.Shots:The validation studies of MI…
July 27, 2021

Read more

Viewpoints_Dr. Andrew Krivoshik
VIEWPOINTS

PharmaShots Interview: Astellas’ Dr. Andrew Krivoshik Shares Insights on P-II FAST Study of Zolbetuximab

In an interview with PharmaShots, Dr. Andrew Krivoshik, Senior Vice President and Oncology Therapeutic Area Head at Astellas, shared his views on the P-II FAST study result published in the journal Gastric Cancer and highlights the data published in Annals of Oncology.Shots:The data from P-II FAST study evaluating zolbetuximab + EOX in 1L patients with advanced gastric and…
July 26, 2021

Read more

Viewpoints_Tony Ezell
VIEWPOINTS

PharmaShots Interview: BD’s Tony Ezell Shares Insights on the Collaboration with USATF to Provide COVID – 19 Testing for US Athletes

In an interview with PharmaShots, Tony Ezell, President, North America and Chief Marketing Officer, BD shares its agreement with the USA Track and Field team for COVID-19 testing for the Olympic Trials.Shots:BD's partnership with USATF is part of the company's commitment to helping get people back to their normal livesThe BD Veritor…
July 21, 2021

Read more

Viewpoints_Dave Marek
VIEWPOINTS

PharmaShots Interview: Myovant’s Dave Marek Shares Insights on the US FDA’s Approval of Myfembree in Uterine Fibroids

In an interview with PharmaShots, Dave Marek. CEO of Myovant shares insights on the US FDA's approval of Myfembree (relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg) in Uterine Fibroids.Shots:The US FDA has approved Myovant & Pfizer's Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as the first once-daily treatment for the…
July 20, 2021

Read more

Viewpoints_Mark Wildgust, Paolo Ghia & Paul Barr
VIEWPOINTS

PharmaShots Interview: Janssen’s Mark Wildgust along with Two Other Key Speakers Share Insights on Data Presented at ASCO 2021

In an interview with PharmaShots, Mark Wildgust, VP of Global Medical Affairs, Oncology at Janssen, Dr. Paolo Ghia, Division of Experimental Oncology at Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele and Paul Barr, Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute at University of Rochester…
July 19, 2021

Read more

Viewpoints_Denis Corin
VIEWPOINTS

PharmaShots Interview: Q BioMed’s Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs

In an interview with PharmaShots, Denis Corin, Chief Executive Officer and Chairman of the Board at Q BioMed share his views on the supply agreement for Strontium89 with the US Department of Defense and Veterans Affairs.Shots:BioMed has signed a 5-year agreement to commercially serve the US Department of Veterans Affairs (VA) and Department of Defense…
July 13, 2021

Read more

Viewpoints_Dr. Ramon Mohanlal
VIEWPOINTS

PharmaShots Interview: BeyondSpring’s Dr. Ramon Mohanlal Shares Insights on the Data of Triple Combo Plinabulin Presented at ASCO 2021

In an interview with PharmaShots, Ramon Mohanlal, M.D., Ph.D., MBA, Chief Medical Officer and Executive Vice President of Research and Development at BeyondSpring share his views on the data of triple combination regimen presented at ASCO and also shed light on the impact of plinabulin on SCLC.Shots:Plinabulin in combination with nivolumab and ipilimumab showed 46% ORR with one…
July 12, 2021

Read more

Load more